The Medicines Patent Pool publishes framework for prioritising target medicines for in-licensing under its newly expanded mandate
The MPP published in May a prioritisation framework that outlines a precise methodology for assessing candidate medicines that could play a major role in the MPP’s expanded mandate into new disease therapies beyond HIV, hepatitis C and tuberculosis.
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries.
The MPP’s patents and licences database, MedsPaL, is a resource that provides information on the intellectual property status of selected HIV, hepatitis C, tuberculosis and other patented essential medicines in low- and middle-income countries.
Innovative licensing agreements continue to provide access to dolutegravir in an unprecedented timeframe
Geneva & London, 30 July 2019. This year marks the fifth anniversary of the signing of two licensing agreements between ViiV Healthcare and the Medicines Patent Pool (MPP) that have allowed generic manufacturers to produce and sell single and combination versions of dolutegravir (DTG) for adults and children in countries with the highest burden of HIV.[i][ii]
Currently, 18 generic manufacturers (17 sublicensees under the MPP and Aurobindo Pharma via a separate direct voluntary licence agreement with ViiV Healthcare) are authorised to produce and sell low-cost single or fixed-dose combination versions of DTG in all least developed, low-income, lower-middle income, and sub-Saharan African countries as well as some other upper middle-income countries (paediatric licence only), totalling 94 and 121 countries for the adult and paediatric agreements respectively.[iii][iv] These licensing agreements...
As the World Health Organization (WHO) releases its guidelines Update of recommendations on first- and second-line antiretroviral regimens, the Medicines Patent Pool (MPP) confirms that high-quality affordable versions of key HIV treatments can already be rolled out in developing countries through MPP generic manufacturing partners and other stakeholders.
The MPP holds licences for dolutegravir (DTG), part of the WHO preferred first- and second-line treatments, which allow generic manufacturers to develop and supply DTG containing regimens to people living with HIV in 94 low- and middle-income countries (adult use) and 121 countries (paediatric use). Seven MPP manufacturing partners have already supplied DTG and DTG-based regimens in 66 countries.
The MPP also holds licences for lopinavir/ritonavir (LPV/r), the recommended preferred second-line treatment when DTG-based regimens have failed; tenofovir alafenamide (TAF), part of WHO-recommended regimens as alternative in children and in special circumstan...
Geneva, 10 July 2019 – This week the World Health Organization (WHO) released its newly updated 21st WHO Model List of Essential Medicines (EML) and 7th WHO Model List of Essential Medicines for children (EMLc), in which key treatments and combinations licensed to the MPP have now been included, namely hepatitis C treatment glecaprevir/pibrentasvir (G/P), antiretroviral regimen tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD) and HIV medicine dolutegravir 50mg for children above 25kg.
“Putting an end to the hepatitis epidemic remains a huge challenge in developing countries so we are very pleased that G/P has been added to the WHO’s Essential Medicines Lists,” said Charles Gore, Executive Director of MPP. "This all-oral, once-daily, pan-genotypic combination regimen is an important new option for people living with chronic hepatitis C.”
“We want people living with HIV in low- and middle-income countries to have access to the best possible treatment at the same time as patients in high-income...
“The Medicines Patent Pool (MPP), a public health organization funded by Unitaid, has played a significant role in facilitating affordable access to essential medicines in the field of HIV and HCV through its public health oriented licences with originator...”
Unable to load twitter timeline, please allow cookie